BioXtek

BioXtek is a pioneering regenerative therapeutics company, harnessing the power of placental birth tissues.

Quality. Integrity. Excellence. Innovation.

BioXtek envisions medical therapeutics derived from human placental tissues and their components to be processed into pharmaceutical grade therapies to regenerate sick or injured tissues at the cellular level.



Our Mission is to bring a new biologic paradigm to allopathic medical treatments for improved patient outcomes in a wide spectrum of medical and surgical pathologies, without side effects or adverse events, and high levels of patient successful outcomes.

Compliant with full cGMP and cGTP standards, supported by a robust and comprehensive quality system, and licensed in all applicable states requiring certification.

Technology Innovation

BioXtek’s manufacturing platform, expansive IP development programs, and regulatory pathways create:

Competitive Advantage

Our approach provides competitive advantage in different markets; each with significant growth potential.

Membrane Patches

Membrane Applications

Membrane patches derived from human placental sac, created in several configurations. 

    Single layer Amnion only, 

    Dual layer Amnion Amnion, or Amnion Chorion, 

    Tri layer Amnion Chorion Amnion, 

    Quad layer Amnion Chorion Chorion Amnion.

Potential areas of use;

Multi Layered membrane configurations available->
single: Amnion,
dual: AmnionAmnion,
Tri : AmnionChorionAmnion,
Quad: AmnionChorionChorionAmnion.
Umbilical patches
Umbilical Powder

Competitive Advantage

Utilizes BioPur process to ensure cell free stable extracellular matrix to provide a consistent membrane patch. Clinical results demonstrating significant consistent wound healing

Potential Applications for Placental tissue derived products:

BioXsomes our therapeutic under study currently is designed for a wide range of medical uses, Longevity – anti aging including wound care, burn treatments, heart, lung, kidney therapies.

Membrane patches have shown success with dura replacement, pericardium coverage and tendon and nerve repair, offering unmatched versatility and effectiveness.

 Proprietary advanced BioPur Process ensures the highest quality and safety by preserving key bioactive molecules, removing impurities, and eliminating the risk of immune reactions.

Future: BioXsomes Therapeutic

BioXtek is pursuing a biologic license from the US FDA.

That will be  an Injectable regenerative therapeutics derived from the contents of 

the umbilical cord and amniotic fluid.

Therapeutic: Fluid Implantable Allograft

Potential Therapeutic Applications

Ongoing Characterizations to build our FDA application.

Averaging 350B protein particles carrying a varying exosome cargo of miRNA, MRNA, proteins, lipids, Growth Factors, Peptides, ECM/collagens, Hyaluronic Acid.

Minimally manipulated concentrate. Available cryopreserved at -80c  or freeze-dried at room temperature .


Topical Cosmetic

Derived from human placental tissue collected from fully consented donors, after full term birth.

We collect all of the  protein particles carrying a varying exosome cargo of miRNA, MRNA, proteins, lipids, Growth Factors, Peptides, Extra cellular matrix/collagens, and Hyaluronic Acid.

Minimally manipulated topically applied concentrate. 

Team

Management

CEO & Founder

Dr Bruce Werber

A seasoned Entrepreneur, Physician and Researcher with over 15 years in the field of regenerative medicine. Dr.

COO & Founder

Terrell Suddarth

Quality and operations management experience in the defense contractor, medical device and biotechnology fields.

CFO

Sunny Sharma

Over 25 years of experience in public, private equity and angel backed entities. Sunny has held several senior management positions.

Advisory Board

Join Our Newsletter

Receive our latest news directly in your inbox!